Bilateral functional worsening following voretigene neparvovec therapy.
作者信息
Rebelo Neves Emmanuel, Carvalho Ana Luísa, Mesquita Teresa, Paiva Catarina, Alfaiate Mário, Figueira João, Murta Joaquim, Marques João Pedro
机构信息
Ophthalmology Unit, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal.
Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal.
出版信息
Eye (Lond). 2023 Sep;37(13):2828-2829. doi: 10.1038/s41433-023-02411-4. Epub 2023 Feb 17.
Abstract
摘要
相似文献
1
Bilateral functional worsening following voretigene neparvovec therapy.使用voretigene neparvovec治疗后双侧功能恶化。
Eye (Lond). 2023 Sep;37(13):2828-2829. doi: 10.1038/s41433-023-02411-4. Epub 2023 Feb 17.
2
Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.Voretigene Neparvovec：治疗 RPE65 基因突变相关遗传性视网膜营养不良的综述。
Mol Diagn Ther. 2020 Aug;24(4):487-495. doi: 10.1007/s40291-020-00475-6.
3
Bilateral Subretinal Voretigene Neparvovec-rzyl (Luxturna) Gene Therapy.双侧视网膜下注射维替泊芬基因治疗药物（Luxturna）基因疗法。
Ophthalmol Retina. 2019 May;3(5):450. doi: 10.1016/j.oret.2019.02.007.
4
Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.治疗 RPE65 介导的遗传性视网膜营养不良患者的 voretigene neparvovec（AAV2-hRPE65v2）的疗效和安全性：一项随机、对照、开放标签、3 期临床试验。
Lancet. 2017 Aug 26;390(10097):849-860. doi: 10.1016/S0140-6736(17)31868-8. Epub 2017 Jul 14.
5
Quantitative Autofluorescence Following Gene Therapy With Voretigene Neparvovec.使用voretigene neparvovec进行基因治疗后的定量自体荧光
JAMA Ophthalmol. 2020 Aug 1;138(8):919-921. doi: 10.1001/jamaophthalmol.2020.2018.
6
Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.用于遗传性视网膜营养不良的voretigene neparvovec-rzyl（Luxturna）。
Med Lett Drugs Ther. 2018 Mar 26;60(1543):53-55.
7
An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK.英国对用于治疗双等位基因 RPE65 介导的遗传性视网膜营养不良的 Voretigene Neparvovec 的经济评估。
Adv Ther. 2020 Mar;37(3):1233-1247. doi: 10.1007/s12325-020-01243-y. Epub 2020 Feb 7.
8
Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl.从首个获得 FDA 批准的基因治疗药物（Voretigene Neparvovec-rzyl）的研发中汲取的经验教训。
Cold Spring Harb Perspect Med. 2023 May 2;13(5):a041307. doi: 10.1101/cshperspect.a041307.
9
Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy.接受 voretigene neparvovec-rzyl 治疗的 RPE65 相关视网膜营养不良的年轻患者的视网膜下沉积物。
Br J Ophthalmol. 2023 Mar;107(3):299-301. doi: 10.1136/bjo-2022-321488. Epub 2022 Jul 14.
10
[Implementation of a new gene therapy in ophthalmology: Regulatory and organizational issues].[眼科新基因治疗的实施：监管与组织问题]
J Fr Ophtalmol. 2021 May;44(5):730-737. doi: 10.1016/j.jfo.2020.10.014. Epub 2021 Apr 8.
本文引用的文献
1
Inflammation after Voretigene Neparvovec Administration in Patients with RPE65-Related Retinal Dystrophy.接受 Voretigene Neparvovec 治疗的 RPE65 相关视网膜营养不良患者的炎症反应。
Ophthalmology. 2022 Nov;129(11):1287-1293. doi: 10.1016/j.ophtha.2022.06.018. Epub 2022 Jun 26.
2
Visual Acuity, Retinal Morphology, and Patients' Perceptions after Voretigene Neparovec-rzyl Therapy for RPE65-Associated Retinal Disease.视觉敏锐度、视网膜形态和 RPE65 相关视网膜疾病接受 Voretigene Neparovec-rzyl 治疗后的患者感知。
Ophthalmol Retina. 2022 Apr;6(4):273-283. doi: 10.1016/j.oret.2021.11.005. Epub 2021 Dec 9.
3
Differential requirement of NPHP1 for compartmentalized protein localization during photoreceptor outer segment development and maintenance.在光感受器外节发育和维持过程中，NPHP1 对分隔蛋白定位的差异需求。
PLoS One. 2021 May 7;16(5):e0246358. doi: 10.1371/journal.pone.0246358. eCollection 2021.
4
Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis.雷柏氏先天性黑蒙 2 型患者经脉络膜视网膜下注射 voretigene neparvovec-rzyl 后出现旁中心凹脉络膜视网膜萎缩
Ophthalmol Retina. 2022 Jan;6(1):58-64. doi: 10.1016/j.oret.2021.03.016. Epub 2021 Apr 8.
5
Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years.双等位基因 RPE65 介导遗传性视网膜疾病的 Voretigene Neparvovec 持久性：3 年和 4 年的 3 期结果。
Ophthalmology. 2021 Oct;128(10):1460-1468. doi: 10.1016/j.ophtha.2021.03.031. Epub 2021 Mar 30.
Zotero 插件